Targeting newly identified ERβ/TGF‐β1/SMAD3 signals with the FDA‐approved anti‐estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma
Open Access
- 30 October 2018
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 12 (12) , 2055-2071
Abstract
Renal cell carcinoma (RCC) has the third highest mortality rate among urological tumors, and 20–30% of RCC patients present with metastatic RCC at the time of diagnosis. Although recent studies have indicated that estrogen receptor β (ERβ) could play promoting roles in RCC progression, the detailed mechanisms remain to be clarified. In the present study, we found that expression of ERβ, but not ERα, increases with tumor stage and grade, and also observed that modification of ERβ signals using estrogens/anti‐estrogens, shRNA knockdown of ERβ and overexpression of ERβ using ectopic cDNA affects RCC cell proliferation, migration and invasion. Mechanism analysis revealed that ERβ can promote RCC cell invasion via an increase in transforming growth factor β1 (TGF‐β1)/SMAD3 signals, and interrupting TGF‐β1/SMAD3 signals with a TGFβR1 inhibitor can reverse/block ERβ‐increased RCC cell migration. Importantly, preclinical analyses using in vivo mouse models of RCC revealed that targeting of this newly identified ERβ/TGF‐β1/SMAD3 pathway with either the FDA‐approved anti‐estrogen ICI182,780 (Faslodex) or a selective ERβ antagonist 4‐[2‐phenyl‐5,7 bis(trifluoromethyl)pyrazolo[1,5‐a]pyrimidin‐3‐yl]phenol can significantly reduce RCC tumor growth and invasion, which may be suitable as the basis for novel therapies to more effectively suppress metastatic RCC.Keywords
Funding Information
- National Natural Science Foundation of China (8167102227)
This publication has 43 references indexed in Scilit:
- Estrogen Inhibits Renal Cell Carcinoma Cell Progression through Estrogen Receptor-β ActivationPLOS ONE, 2013
- miR‐145 is differentially regulated by TGF‐β1 and ischaemia and targets Disabled‐2 expression and wnt/β‐catenin activityJournal of Cellular and Molecular Medicine, 2012
- Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladderBJU International, 2012
- Cytoplasmic Estrogen Receptor in Breast CancerClinical Cancer Research, 2012
- Estrogen receptor β and 17β-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancerProceedings of the National Academy of Sciences, 2011
- ERβ in breast cancer—Onlooker, passive player, or active protector?Steroids, 2008
- Relationship between Estrogen Receptor-Binding and Estrogenic Activities of Environmental Estrogens and Suppression by FlavonoidsBioscience, Biotechnology, and Biochemistry, 2002
- Estrogen treatment enhances hereditary renal tumor development in Eker ratsCarcinogenesis, 1998
- Cloning of a novel receptor expressed in rat prostate and ovary.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Hormonal therapy for metastatic renal cell carcinoma combined androgen and provera followed by high dose tamoxifenEuropean Journal of Cancer, 1993